Developer docs
API playgroundTry for free, no card

Search company profiles

Adial Pharmaceuticals

Full company profile

uuid00025ts

Namestring
Adial Pharmaceuticals
Legal namestring
Adial Pharmaceuticals, Inc.
Websiteurl
adialpharma.com
Company typeenum
Public
Founded yearint
2010
Descriptiontext

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Glen Allen, Virginia, founded in 2010 and listed on NASDAQ under ticker ADIL. The company develops genetically targeted therapeutics, with its lead candidate AD04 positioned as a precision-medicine treatment for Alcohol Use Disorder (AUD) and its secondary candidate AT177 targeting ulcerative colitis following the June 2026 acquisition of Azora Therapeutics. The intended patient population spans individuals with alcohol addiction and those suffering from inflammatory bowel disease, with therapeutic activity matched to genetically defined responder subgroups.

The company's core technology centers on biomarker-driven patient stratification. AD04 is paired with a companion diagnostic developed with Genomind that reportedly identifies patients with specific genetic profiles linked to serotonin signaling pathways, with stated 100% concordance in identifying suitable candidates for therapy. Adial is pursuing patent protection for AD04 through 2045 and filed an FDA Priority Voucher application in April 2026 to accelerate potential regulatory review. The organization employs 11-50 staff and is organized around clinical development rather than commercial operations.

The business model is currently pre-commercial: Adial does not generate product revenue and operates at an annual net loss of approximately $8.0 million (2025), funded through equity financings. Capital sources have included multiple small raises, a $5.9 million round into H2 2026, and a $32 million PIPE in June 2026 led by Coastlands Capital. Future revenue mechanics, contingent on regulatory approval, contemplate direct product sales in the US and partnership-driven commercialization in Europe via the Molteni Farmaceutici agreement signed March 2026 (potential deal value approximately $60 million). The company executed a 1-for-25 reverse stock split in February 2026 to maintain NASDAQ compliance.

Short descriptiontext

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company developing genetically targeted therapeutics, including AD04 for Alcohol Use Disorder and AT177 for ulcerative colitis, serving patients with addiction and inflammatory diseases through a precision-medicine approach with companion diagnostics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGlen Allen, United States
HQ citystring
Glen Allen
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
alcohol use disorder treatment, genetically targeted therapy, clinical-stage biopharmaceutical, ulcerative colitis drug development, addiction therapeutics pipeline
Industry2 codes
PRIMARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-stage Biopharmaceuticals (Addiction Therapeutics)
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1AD04
Description

Genetically targeted serotonin-3 receptor antagonist being advanced through Phase 3 clinical trial program for treatment of Alcohol Use Disorder in patients with certain target genotypes

adial.com
+1 more record
Core offering1 text field

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company developing two prescription drug candidates: AD04, a genetically targeted serotonin-3 receptor antagonist advancing through a Phase 3 clinical trial program for the treatment of Alcohol Use Disorder in patients with specific target genotypes, and AT177, a novel colon-targeted aryl hydrocarbon receptor (AhR) agonist acquired from Azora Therapeutics in June 2026 for the treatment of ulcerative colitis. The company is pre-revenue and focuses on advancing these candidates through regulatory milestones toward commercial launch.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Net loss narrowed from $13.2M (2024) to $8.0M (2025)
+3 more records
Product overview1 text field

Adial Pharmaceuticals is a biopharmaceutical company with a pipeline of two distinct drug candidates following its acquisition of Azora Therapeutics. The core product is AD04, a genetically targeted serotonin-3 receptor antagonist for Alcohol Use Disorder currently in Phase 3 clinical trials. The second product is AT177, a colon-targeted AhR agonist acquired from Azora Therapeutics for ulcerative colitis, expected to enter Phase 1 trials in mid-2027. The company operates as a clinical-stage developer without a unified platform architecture.

Product and service1 record
1AD04
Scale indicator18 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-11
Description

Adial Pharmaceuticals acquired Azora Therapeutics for $32 million, bringing AT177—a proprietary colon-targeted aryl hydrocarbon receptor agonist for ulcerative colitis—into its pipeline. Following the transaction, Azora equity holders own approximately 51% of the combined company on a fully-diluted basis. Phase 1 clinical trials for AT177 are planned for mid-2027.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-03
Description

Collaboration framework agreement for exclusive European partnership to commercialize AD04, a serotonin-3 receptor antagonist treatment for Alcohol Use Disorder. Deal includes upfront payment, milestone payments, and tiered royalties ranging from high single digits to low double digits, with total potential value estimated at nearly $60 million contingent on successful development and market introduction. Partnership requires execution of final definitive agreement.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-10
Description

Collaboration with Genomind enabled successful validation of cheek swab collection method for genetic testing related to AD04 program. Testing of specific SNPs achieved 100% concordance, supporting regulatory progress towards Phase 3 trials and commercial deployment of companion diagnostic.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Alkermes markets Vivitrol (naltrexone), an approved therapy for Alcohol Use Disorder, making it the most directly comparable commercial-stage peer to Adial's AD04 AUD asset. Both companies target CNS/addiction therapeutics with similar specialty-pharma positioning.

TypeDirect peer
Description

Indivior is a global leader in addiction therapeutics (Suboxone, Sublocade for opioid use disorder) and is expanding into AUD. Direct overlap with Adial's addiction-treatment focus and similar specialty pharma commercial model.

TypeEmerging player
Description

Swedish specialty pharma developing long-acting injectable therapies for opioid use disorder and chronic pain using FluidCrystal technology. Comparable as an emerging CNS/addiction therapeutics developer with similar pipeline-stage profile.

TypeEmerging player
Description

Axsome is a clinical-stage and commercial CNS specialty pharma (Auvelity for depression, Sunosi for narcolepsy). Similar small-cap, CNS-focused, specialty-pharma profile with pipeline-stage parallels to Adial.

TypeEmerging player
Description

Sage is a CNS-focused specialty biopharma (Zurzuvae for postpartum depression, collaborations with Biogen). Comparable as a small/mid-cap CNS specialty developer with similar regulatory-pathway and approval-cycle dynamics.

TypeEmerging player
Description

BioXcel is a clinical-stage biopharma developing neuroscience and immuno-oncology therapies (Igalmi for agitation in schizophrenia/bipolar). Comparable as an emerging CNS-focused specialty pharma with similar capital-raise and regulatory-milestone profile.

TypeEmerging player
Description

Tonix is a clinical-stage CNS specialty pharma developing therapies for migraine, fibromyalgia, and PTSD. Comparable as a small-cap CNS pipeline developer with similar financial profile and reliance on capital markets.

TypeBroad incumbent
Description

AbbVie markets Skyrizi and Rinvoq, both approved for ulcerative colitis, and is the dominant incumbent in inflammatory bowel disease. Directly comparable to the AT177 ulcerative colitis opportunity in terms of competitive landscape and market dynamics.

TypeBroad incumbent
Description

Pfizer markets etrasimod (Velsipity) for ulcerative colitis (acquired via Arena Pharmaceuticals) and is a broad incumbent in GI/inflammation. Comparable on the AT177 competitive landscape and as a large biopharma with strategic interest in IBD.

10Bristol Myers Squibb
TypeBroad incumbent
Description

BMS markets Zeposia (ozanimod) for ulcerative colitis and is a broad incumbent in inflammatory/autoimmune disease. Comparable on AT177's competitive context and as a major biopharma with established IBD commercial infrastructure.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Adial Pharmaceuticals

Clinical-stage Biopharmaceuticals (Addiction Therapeutics)adialpharma.com

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company developing genetically targeted therapeutics, including AD04 for Alcohol Use Disorder and AT177 for ulcerative colitis, serving patients with addiction and inflammatory diseases through a precision-medicine approach with companion diagnostics.

What Adial Pharmaceuticals does

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Glen Allen, Virginia, founded in 2010 and listed on NASDAQ under ticker ADIL. The company develops genetically targeted therapeutics, with its lead candidate AD04 positioned as a precision-medicine treatment for Alcohol Use Disorder (AUD) and its secondary candidate AT177 targeting ulcerative colitis following the June 2026 acquisition of Azora Therapeutics. The intended patient population spans individuals with alcohol addiction and those suffering from inflammatory bowel disease, with therapeutic activity matched to genetically defined responder subgroups.

The company's core technology centers on biomarker-driven patient stratification. AD04 is paired with a companion diagnostic developed with Genomind that reportedly identifies patients with specific genetic profiles linked to serotonin signaling pathways, with stated 100% concordance in identifying suitable candidates for therapy. Adial is pursuing patent protection for AD04 through 2045 and filed an FDA Priority Voucher application in April 2026 to accelerate potential regulatory review. The organization employs 11-50 staff and is organized around clinical development rather than commercial operations.

The business model is currently pre-commercial: Adial does not generate product revenue and operates at an annual net loss of approximately $8.0 million (2025), funded through equity financings. Capital sources have included multiple small raises, a $5.9 million round into H2 2026, and a $32 million PIPE in June 2026 led by Coastlands Capital. Future revenue mechanics, contingent on regulatory approval, contemplate direct product sales in the US and partnership-driven commercialization in Europe via the Molteni Farmaceutici agreement signed March 2026 (potential deal value approximately $60 million). The company executed a 1-for-25 reverse stock split in February 2026 to maintain NASDAQ compliance.

Adial Pharmaceuticals firmographics

Firmographics
Name
Adial Pharmaceuticals
Legal name
Adial Pharmaceuticals, Inc.
Website
https://adialpharma.com
Company type
Public
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company developing genetically targeted therapeutics, including AD04 for Alcohol Use Disorder and AT177 for ulcerative colitis, serving patients with addiction and inflammatory diseases through a precision-medicine approach with companion diagnostics.
Ownership category
akta.pro rank

Adial Pharmaceuticals industry classification

Industry
Product category
Clinical-stage Biopharmaceuticals (Addiction Therapeutics)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Alcohol use disorder treatment
  • Genetically targeted therapy
  • Clinical-stage biopharmaceutical
  • Ulcerative colitis drug development
  • Addiction therapeutics pipeline

Where Adial Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Glen Allen
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Adial Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Distribution channels2 records

Marketing channels6 records

Adial Pharmaceuticals product offering

Product offering

Core offering

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company developing two prescription drug candidates: AD04, a genetically targeted serotonin-3 receptor antagonist advancing through a Phase 3 clinical trial program for the treatment of Alcohol Use Disorder in patients with specific target genotypes, and AT177, a novel colon-targeted aryl hydrocarbon receptor (AhR) agonist acquired from Azora Therapeutics in June 2026 for the treatment of ulcerative colitis. The company is pre-revenue and focuses on advancing these candidates through regulatory milestones toward commercial launch.

Product overview

Adial Pharmaceuticals is a biopharmaceutical company with a pipeline of two distinct drug candidates following its acquisition of Azora Therapeutics. The core product is AD04, a genetically targeted serotonin-3 receptor antagonist for Alcohol Use Disorder currently in Phase 3 clinical trials. The second product is AT177, a colon-targeted AhR agonist acquired from Azora Therapeutics for ulcerative colitis, expected to enter Phase 1 trials in mid-2027. The company operates as a clinical-stage developer without a unified platform architecture.

Differentiator

Problem solved

Functional benefit

Brands

  • AD04: Genetically targeted serotonin-3 receptor antagonist being advanced through Phase 3 clinical trial program for treatment of Alcohol Use Disorder in patients with certain target genotypes
  • AT177

Products and services

  • AD04

Quantifiable outcome

  • Net loss narrowed from $13.2M (2024) to $8.0M (2025)
  • +3 more outcomes

Companies that use Adial Pharmaceuticals

Customer profile

Segments2 records

Ideal customer profiles2 records

Adial Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Adial Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Azora TherapeuticscoreStrategic or Co-development Partner · 11 June 2026Adial Pharmaceuticals acquired Azora Therapeutics for $32 million, bringing AT177—a proprietary colon-targeted aryl hydrocarbon receptor agonist for ulcerative colitis—into its pipeline. Following the transaction, Azora equity holders own approximately 51% of the combined company on a fully-diluted basis. Phase 1 clinical trials for AT177 are planned for mid-2027.
  • Molteni FarmaceuticicoreChannel Partner/ Reseller/ Distributor · 3 March 2026Collaboration framework agreement for exclusive European partnership to commercialize AD04, a serotonin-3 receptor antagonist treatment for Alcohol Use Disorder. Deal includes upfront payment, milestone payments, and tiered royalties ranging from high single digits to low double digits, with total potential value estimated at nearly $60 million contingent on successful development and market introduction. Partnership requires execution of final definitive agreement.
  • GenomindcoreTechnology or Integration · 10 October 2025Collaboration with Genomind enabled successful validation of cheek swab collection method for genetic testing related to AD04 program. Testing of specific SNPs achieved 100% concordance, supporting regulatory progress towards Phase 3 trials and commercial deployment of companion diagnostic.

Scale indicators18 records

Recent moves6 records

Expansion highlights7 records

Adial Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Alkermes: Alkermes markets Vivitrol (naltrexone), an approved therapy for Alcohol Use Disorder, making it the most directly comparable commercial-stage peer to Adial's AD04 AUD asset. Both companies target CNS/addiction therapeutics with similar specialty-pharma positioning.
  • Indivior: Indivior is a global leader in addiction therapeutics (Suboxone, Sublocade for opioid use disorder) and is expanding into AUD. Direct overlap with Adial's addiction-treatment focus and similar specialty pharma commercial model.

Emerging players

  • Camurus: Swedish specialty pharma developing long-acting injectable therapies for opioid use disorder and chronic pain using FluidCrystal technology. Comparable as an emerging CNS/addiction therapeutics developer with similar pipeline-stage profile.
  • Axsome Therapeutics: Axsome is a clinical-stage and commercial CNS specialty pharma (Auvelity for depression, Sunosi for narcolepsy). Similar small-cap, CNS-focused, specialty-pharma profile with pipeline-stage parallels to Adial.
  • Sage Therapeutics: Sage is a CNS-focused specialty biopharma (Zurzuvae for postpartum depression, collaborations with Biogen). Comparable as a small/mid-cap CNS specialty developer with similar regulatory-pathway and approval-cycle dynamics.
  • BioXcel Therapeutics: BioXcel is a clinical-stage biopharma developing neuroscience and immuno-oncology therapies (Igalmi for agitation in schizophrenia/bipolar). Comparable as an emerging CNS-focused specialty pharma with similar capital-raise and regulatory-milestone profile.
  • Tonix Pharmaceuticals: Tonix is a clinical-stage CNS specialty pharma developing therapies for migraine, fibromyalgia, and PTSD. Comparable as a small-cap CNS pipeline developer with similar financial profile and reliance on capital markets.

Broad incumbents

  • AbbVie: AbbVie markets Skyrizi and Rinvoq, both approved for ulcerative colitis, and is the dominant incumbent in inflammatory bowel disease. Directly comparable to the AT177 ulcerative colitis opportunity in terms of competitive landscape and market dynamics.
  • Pfizer: Pfizer markets etrasimod (Velsipity) for ulcerative colitis (acquired via Arena Pharmaceuticals) and is a broad incumbent in GI/inflammation. Comparable on the AT177 competitive landscape and as a large biopharma with strategic interest in IBD.
  • Bristol Myers Squibb: BMS markets Zeposia (ozanimod) for ulcerative colitis and is a broad incumbent in inflammatory/autoimmune disease. Comparable on AT177's competitive context and as a major biopharma with established IBD commercial infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Adial Pharmaceuticals social profiles

Digital presence

Adial Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Adial Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles9 records

Adial Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Adial Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Adial Pharmaceuticals M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adial Pharmaceuticals

What does Adial Pharmaceuticals do?

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company developing two prescription drug candidates: AD04, a genetically targeted serotonin-3 receptor antagonist advancing through a Phase 3 clinical trial program for the treatment of Alcohol Use Disorder in patients with specific target genotypes, and AT177, a novel colon-targeted aryl hydrocarbon receptor (AhR) agonist acquired from Azora Therapeutics in June 2026 for the treatment of ulcerative colitis. The company is pre-revenue and focuses on advancing these candidates through regulatory milestones toward commercial launch.

Is Adial Pharmaceuticals a public or private company?

Adial Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Adial Pharmaceuticals founded?

Adial Pharmaceuticals was founded in 2010. It employs 11 to 50 people.

Where is Adial Pharmaceuticals based?

Adial Pharmaceuticals is headquartered in Glen Allen, United States, in the North America region.

Who are Adial Pharmaceuticals's main competitors?

Direct peers on record are Alkermes and Indivior. Emerging players are Camurus, Axsome Therapeutics, Sage Therapeutics, BioXcel Therapeutics and Tonix Pharmaceuticals. Broad incumbents are AbbVie, Pfizer and Bristol Myers Squibb.

Does Adial Pharmaceuticals have an API?

No public API is recorded for Adial Pharmaceuticals.

What industry is Adial Pharmaceuticals in?

Adial Pharmaceuticals's product category is Clinical-stage Biopharmaceuticals (Addiction Therapeutics). Its primary akta.pro industry code is HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals, with a secondary code of HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingAdial Pharmaceuticals Files Initial Beneficial Ownership Statement for CFO Vassiliki EconomidesAdial Pharmaceuticals CFO Vassiliki Economides filed an initial beneficial ownership statement disclosing stock options to buy 307,814 common shares at $5.76. The filing was published via EDGAR on October 30, 2026.TradingViewAdial Pharmaceuticals appoints Davidson, Economides and Saiki to leadership rolesAdial Pharmaceuticals appointed Matthew Davidson as CEO, Celia Economides as CFO, and Julie Saiki as chief strategy officer, effective October 28, 2026. Cary J. Claiborne and Vinay Shah departed, with Economides and Saiki taking over their roles. Existing compensation arrangements remain unchanged.Seeking AlphaAdial Pharmaceuticals to appoint Celia Economides as CFO (ADIL:NASDAQ)Adial Pharmaceuticals announced that Celia Economides, its current executive vice president of finance, will be appointed chief financial officer after the company's reconvened 2026 annual meeting. She will succeed Vinay Shah, and Economides previously served as CFO of CellCentric and Gritstone Bio.TradingViewAdial Pharmaceuticals adjourns votes on Nasdaq-dependent proposals, reconvenes meeting Oct. 26Adial Pharmaceuticals adjourned votes on Proposals 3-6 at its 2026 Annual Meeting while awaiting Nasdaq approval of its listing application. The meeting reconvened Oct. 15 but further adjourned those proposals, with polls still open and a reconvening set for Oct. 26 at 8:30 a.m. ET in Charlottesville.The future of tradingAdial Pharmaceuticals Appoints David Rubenstein as Chief ScientistAdial Pharmaceuticals appointed David Rubenstein as chief scientist to lead research and scientific strategy. He previously served as Dermavant Sciences' chief scientific officer, leading tapinarof development. He will oversee AT177 development for ulcerative colitis, with first-in-human trials expected in 2027.BioSpaceAdial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - September 30, 2026Adial Pharmaceuticals granted a new employee stock option to purchase 155,446 shares at $4.22 per share, with a ten-year term and four-year vesting. The award was made outside equity incentive plans under Nasdaq Listing Rule 5635(c)(4). The company's lead program AT177 is in IND-enabling studies, with an IND filing planned for the first half of 2027.Markets DailyAdial Pharmaceuticals, Inc. (NASDAQ:ADIL) Stock Has Average Target Price of $15.62 According to AnalystsAnalysts rate Adial Pharmaceuticals with a consensus 'Hold' and an average price target of $8.33. The stock opened at $4.15, and the company reported a Q2 loss of $11.25 per share, missing the consensus estimate of -$1.03. Major shareholder Coastlands Capital Lp acquired 10,053 shares at $2.79 each.AInvestA Dial Pharmaceuticals - Proposed resale of up to 25,148,970 shares of common stock by selling stockholders - SEC filingA Dial Pharmaceuticals, Inc. filed with the U.S. Securities and Exchange Commission to register the proposed resale of up to 25,148,970 shares of its common stock by selling stockholders. The filing, part of the company's ongoing capital structure management, discloses no price, timing, or proceeds. The company has not indicated whether it will receive any proceeds from the resale.BioSpaceAdial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - August 25, 2026Adial Pharmaceuticals granted a new employee stock option to purchase 307,814 shares at $5.76 per share, with a ten-year term and four-year vesting. The award was made outside equity incentive plans under Nasdaq Listing Rule 5635(c)(4). The company's lead program AT177 is in IND-enabling studies, with an IND filing planned for the first half of 2027.Markets DailyAdial Pharmaceuticals (NASDAQ:ADIL) versus Journey Medical (NASDAQ:DERM) Critical ReviewA MarketBeat comparison evaluated small-cap healthcare stocks Journey Medical and Adial Pharmaceuticals across valuation, risk, earnings, institutional ownership, analyst ratings and profitability. Adial Pharmaceuticals beat Journey Medical on eight of thirteen factors, with 16.4% institutional ownership versus 7.2% and a consensus target of $15.62 versus $14.00.